Compare Sun Pharma with GSK Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SUN PHARMA vs GSK PHARMA - Comparison Results

SUN PHARMA     Change

Sun Pharma holds 3.7% share of the domestic pharma market (as per the latest ORG IMS MAT data) and has a strong presence in the lifestyle therapeutic segments. The company started focusing on the exports market in FY02, when it increased its stake to... More

GSK PHARMA 
   Change

GSK Pharma is one of the leading MNC pharma companies in the Indian market. It is a 50.7% subsidiary of GlaxoSmithKline Plc, one of the world's largest pharma companies. GSK Pharma's product portfolio boasts of some of the leading brands like Augment... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SUN PHARMA GSK PHARMA SUN PHARMA/
GSK PHARMA
 
P/E (TTM) x 28.4 228.9 12.4% View Chart
P/BV x 2.9 11.8 24.4% View Chart
Dividend Yield % 0.6 1.3 41.4%  

Financials

 SUN PHARMA   GSK PHARMA
EQUITY SHARE DATA
    SUN PHARMA
Mar-19
GSK PHARMA
Mar-19
SUN PHARMA/
GSK PHARMA
5-Yr Chart
Click to enlarge
High Rs6793,595 18.9%   
Low Rs3751,253 30.0%   
Sales per share (Unadj.) Rs121.1184.7 65.6%  
Earnings per share (Unadj.) Rs13.426.3 50.9%  
Cash flow per share (Unadj.) Rs20.729.2 70.9%  
Dividends per share (Unadj.) Rs2.7520.00 13.8%  
Dividend yield (eoy) %0.50.8 63.2%  
Book value per share (Unadj.) Rs172.6126.3 136.6%  
Shares outstanding (eoy) m2,399.26169.40 1,416.3%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.413.1 33.1%   
Avg P/E ratio x39.492.2 42.7%  
P/CF ratio (eoy) x25.583.1 30.7%  
Price / Book Value ratio x3.119.2 15.9%  
Dividend payout %20.676.1 27.0%   
Avg Mkt Cap Rs m1,264,650410,626 308.0%   
No. of employees `00017.55.0 352.8%   
Total wages/salary Rs m59,6715,372 1,110.8%   
Avg. sales/employee Rs Th16,608.16,306.7 263.3%   
Avg. wages/employee Rs Th3,409.61,083.1 314.8%   
Avg. net profit/employee Rs Th1,833.8898.0 204.2%   
INCOME DATA
Net Sales Rs m290,65931,281 929.2%  
Other income Rs m10,2551,023 1,002.3%   
Total revenues Rs m300,91432,304 931.5%   
Gross profit Rs m63,0766,009 1,049.7%  
Depreciation Rs m17,533486 3,607.5%   
Interest Rs m5,5536 92,541.7%   
Profit before tax Rs m50,2466,540 768.3%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-12,144287 -4,231.3%   
Tax Rs m6,0092,373 253.2%   
Profit after tax Rs m32,0934,454 720.5%  
Gross profit margin %21.719.2 113.0%  
Effective tax rate %12.036.3 33.0%   
Net profit margin %11.014.2 77.5%  
BALANCE SHEET DATA
Current assets Rs m310,69220,061 1,548.7%   
Current liabilities Rs m173,39614,543 1,192.3%   
Net working cap to sales %47.217.6 267.8%  
Current ratio x1.81.4 129.9%  
Inventory Days Days9957 174.5%  
Debtors Days Days11214 793.5%  
Net fixed assets Rs m232,47714,343 1,620.9%   
Share capital Rs m2,3991,694 141.6%   
"Free" reserves Rs m411,69119,704 2,089.4%   
Net worth Rs m414,09121,398 1,935.2%   
Long term debt Rs m15,2262 761,305.0%   
Total assets Rs m646,93839,113 1,654.0%  
Interest coverage x10.01,091.0 0.9%   
Debt to equity ratio x00 39,340.7%  
Sales to assets ratio x0.40.8 56.2%   
Return on assets %5.811.4 51.0%  
Return on equity %7.820.8 37.2%  
Return on capital %10.231.9 31.8%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m66,025534 12,364.3%   
Fx outflow Rs m38,6107,091 544.5%   
Net fx Rs m27,415-6,557 -418.1%   
CASH FLOW
From Operations Rs m21,9653,994 550.0%  
From Investments Rs m-6,813-1,433 475.3%  
From Financial Activity Rs m-27,305-3,584 761.9%  
Net Cashflow Rs m-8,442-1,023 825.0%  

Share Holding

Indian Promoters % 63.7 0.0 -  
Foreign collaborators % 0.0 50.7 -  
Indian inst/Mut Fund % 5.1 10.2 50.3%  
FIIs % 23.0 23.8 96.6%  
ADR/GDR % 0.0 0.0 -  
Free float % 8.3 15.4 53.9%  
Shareholders   133,026 102,036 130.4%  
Pledged promoter(s) holding % 0.5 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SUN PHARMA With:   PROCTER & GAMBLE HEALTH  CIPLA  ASTRAZENECA PHARMA  SUVEN LIFESCIENCES  STERLING BIOTECH  

Compare SUN PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 143 Points Lower; Banking and Finance Stocks Witness Selling(Closing)

Indian share markets witnessed selling pressure throughout the day today, tracking weak global cues as coronavirus cases continue to surge across the world.

Related Views on News

SUN PHARMA Announces Quarterly Results (4QFY20); Net Profit Down 31.6% (Quarterly Result Update)

May 28, 2020 | Updated on May 28, 2020

For the quarter ended March 2020, SUN PHARMA has posted a net profit of Rs 5 bn (down 31.6% YoY). Sales on the other hand came in at Rs 82 bn (up 14.3% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

SUN PHARMA Announces Quarterly Results (3QFY20); Net Profit Down 29.8% (Quarterly Result Update)

Feb 7, 2020 | Updated on Feb 7, 2020

For the quarter ended December 2019, SUN PHARMA has posted a net profit of Rs 10 bn (down 29.8% YoY). Sales on the other hand came in at Rs 82 bn (up 5.4% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

GSK PHARMA Announces Quarterly Results (2QFY20); Net Profit Up 398.9% (Quarterly Result Update)

Oct 25, 2019 | Updated on Oct 25, 2019

For the quarter ended September 2019, GSK PHARMA has posted a net profit of Rs 5 bn (up 398.9% YoY). Sales on the other hand came in at Rs 9 bn (up 8.1% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

SUN PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 35.3% (Quarterly Result Update)

Aug 14, 2019 | Updated on Aug 14, 2019

For the quarter ended June 2019, SUN PHARMA has posted a net profit of Rs 15 bn (up 35.3% YoY). Sales on the other hand came in at Rs 84 bn (up 15.9% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

SUN PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Aug 6, 2019 | Updated on Aug 6, 2019

Here's an analysis of the annual report of SUN PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of SUN PHARMA. Also includes updates on the valuation of SUN PHARMA.

More Views on News

Most Popular

How to Find the Best Stocks for Day Trading - 1(Fast Profits Daily)

Jul 2, 2020

In the first of two videos, I'll show you how to identify the best stocks for intraday trading.

Two Agri Stocks Are Likely to Outperform Even in this Market(Profit Hunter)

Jul 2, 2020

Why we have recommended two agriculture stocks for our Hidden Treasure subscribers. Read on...

A Warning for Traders: Don't Get Addicted to Hopium(Fast Profits Daily)

Jun 30, 2020

If you are a trader, you must watch out for this dangerous addiction.

Smallcaps Are in a Sweet Spot Again: Are You Buying?(Profit Hunter)

Jul 3, 2020

This is why I believe smallcaps are the place to be in the near future.

More

India's #1 Trader
Reveals His Secrets

The Secret to Increasing Your Trading Profits Today
Get this Special Report, The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

SUN PHARMA SHARE PRICE


Jul 10, 2020 (Close)

TRACK SUN PHARMA

  • Track your investment in SUN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

SUN PHARMA - PIRAMAL ENTERPRISES COMPARISON

COMPARE SUN PHARMA WITH

MARKET STATS